免疫疗法治疗胶质母细胞瘤的现状。
Current State of Immunotherapy for Treatment of Glioblastoma.
机构信息
Department of Neurology, UW Medicine, University of Washington, Seattle, WA, USA.
Department of Neurology, Stanford University, Stanford, CA, USA.
出版信息
Curr Treat Options Oncol. 2019 Feb 21;20(3):24. doi: 10.1007/s11864-019-0619-4.
Abstract
At this time, there are no FDA-approved immune therapies for glioblastoma (GBM) despite many unique therapies currently in clinical trials. GBM is a highly immunosuppressive tumor and there are limitations to a safe immune response in the central nervous system. To date, there have been several failures of phase 3 immune therapy clinical trials in GBM. These trials have targeted single components of an antitumor immune response. Learning from these failures, the future of immunotherapy for GBM appears most hopeful for combination of immune therapies to overcome the profound immunosuppression of this disease. Understanding biomarkers for appropriate patient selection as well as tumor progression are necessary for implementation of immunotherapy for GBM.
摘要
目前，尽管有许多独特的疗法正在临床试验中，胶质母细胞瘤（GBM）仍没有获得 FDA 批准的免疫疗法。GBM 是一种高度免疫抑制性肿瘤，在中枢神经系统中安全的免疫反应存在局限性。迄今为止，已有几项针对 GBM 的 3 期免疫治疗临床试验失败。这些试验的靶点是抗肿瘤免疫反应的单一成分。从这些失败中吸取教训，GBM 免疫治疗的未来似乎最有希望通过联合免疫治疗来克服这种疾病的深度免疫抑制。了解适合患者选择和肿瘤进展的生物标志物对于 GBM 的免疫治疗的实施是必要的。
相似文献
1
Current State of Immunotherapy for Treatment of Glioblastoma.免疫疗法治疗胶质母细胞瘤的现状。
Curr Treat Options Oncol. 2019 Feb 21;20(3):24. doi: 10.1007/s11864-019-0619-4.
2
Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.多形性胶质母细胞瘤患者实验性靶向治疗和免疫治疗的进展
Anticancer Res. 2017 Jan;37(1):21-33. doi: 10.21873/anticanres.11285.
3
Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.胶质母细胞瘤中免疫检查点阻断的临床试验研究
Curr Treat Options Oncol. 2017 Aug;18(8):51. doi: 10.1007/s11864-017-0492-y.
4
Treatment Progress of Immune Checkpoint Blockade Therapy for Glioblastoma.免疫检查点阻断疗法治疗胶质母细胞瘤的研究进展。
Front Immunol. 2020 Nov 30;11:592612. doi: 10.3389/fimmu.2020.592612. eCollection 2020.
5
Glioblastoma targeted therapy: updated approaches from recent biological insights.胶质母细胞瘤靶向治疗：基于近期生物学见解的更新方法。
Ann Oncol. 2017 Jul 1;28(7):1457-1472. doi: 10.1093/annonc/mdx106.
6
Immunotherapy as a New Therapeutic Approach for Brain and Spinal Cord Tumors.免疫疗法作为脑和脊髓肿瘤的一种新治疗方法。
Adv Exp Med Biol. 2023;1394:73-84. doi: 10.1007/978-3-031-14732-6_5.
7
An Update on the Role of Immunotherapy and Vaccine Strategies for Primary Brain Tumors.原发性脑肿瘤免疫治疗和疫苗策略作用的最新进展
Curr Treat Options Oncol. 2015 Nov;16(11):54. doi: 10.1007/s11864-015-0371-3.
8
Glioblastoma Immunotherapy: A Systematic Review of the Present Strategies and Prospects for Advancements.胶质母细胞瘤免疫治疗：现有策略的系统评价及进展展望。
Int J Mol Sci. 2023 Oct 10;24(20):15037. doi: 10.3390/ijms242015037.
9
Extrinsic factors associated with the response to immunotherapy in glioblastoma.与胶质母细胞瘤免疫治疗反应相关的外在因素。
Cancer Lett. 2021 Jul 28;511:47-55. doi: 10.1016/j.canlet.2021.04.018. Epub 2021 Apr 29.
10
Emerging immunotherapies for glioblastoma.胶质母细胞瘤的新兴免疫疗法。
Expert Opin Emerg Drugs. 2016 Jun;21(2):133-45. doi: 10.1080/14728214.2016.1186643.
引用本文的文献
1
Xenoline-polarized macrophages as an alternative in vitro model of tumor-associated macrophages in glioblastoma.异种源极化巨噬细胞作为胶质母细胞瘤中肿瘤相关巨噬细胞的一种体外替代模型。
Acta Neuropathol Commun. 2025 Jun 28;13(1):137. doi: 10.1186/s40478-025-02057-1.
2
Research progress of galectins in glioma.半乳糖凝集素在神经胶质瘤中的研究进展
Discov Oncol. 2025 Jun 4;16(1):1003. doi: 10.1007/s12672-025-02318-4.
3
Xenoline-polarized macrophages as a physiologically relevant in vitro model of tumor-associated macrophages in glioblastoma.异壬醇极化巨噬细胞作为胶质母细胞瘤中肿瘤相关巨噬细胞的一种生理相关体外模型。
Res Sq. 2025 May 9:rs.3.rs-6567445. doi: 10.21203/rs.3.rs-6567445/v1.
4
Immune response recalibration using immune therapy and biomimetic nano-therapy against high-grade gliomas and brain metastases.利用免疫疗法和仿生纳米疗法对高级别胶质瘤和脑转移瘤进行免疫反应重新校准。
Asian J Pharm Sci. 2025 Apr;20(2):101021. doi: 10.1016/j.ajps.2025.101021. Epub 2025 Jan 17.
5
Advances in bioengineered CAR T/NK cell therapy for glioblastoma: Overcoming immunosuppression and nanotechnology-based strategies for enhanced CAR T/NK cell therapy.用于胶质母细胞瘤的生物工程化嵌合抗原受体T细胞/自然杀伤细胞疗法的进展：克服免疫抑制及基于纳米技术增强嵌合抗原受体T细胞/自然杀伤细胞疗法的策略
Bioeng Transl Med. 2024 Aug 31;10(2):e10716. doi: 10.1002/btm2.10716. eCollection 2025 Mar.
6
Improving IL12 immunotherapy in glioblastoma by targeting the long noncoding RNA INCR1.通过靶向长链非编码RNA INCR1改善胶质母细胞瘤中的IL12免疫疗法。
J Neurooncol. 2025 May;173(1):205-216. doi: 10.1007/s11060-025-04978-2. Epub 2025 Mar 4.
7
Dual nuclear receptor 4A1 (NR4A1/NR4A2) ligands inhibit glioblastoma growth and target TWIST1.双核受体4A1（NR4A1/NR4A2）配体抑制胶质母细胞瘤生长并以TWIST1为靶点。
Mol Pharmacol. 2025 Feb;107(2):100009. doi: 10.1016/j.molpha.2024.100009. Epub 2024 Dec 31.
8
Functional profiling of murine glioma models highlights targetable immune evasion phenotypes.功能分析揭示了靶向治疗的免疫逃避表型。
Acta Neuropathol. 2024 Nov 27;148(1):74. doi: 10.1007/s00401-024-02831-w.
9
Reduced T and NK Cell Activity in Glioblastoma Patients Correlates with TIM-3 and BAT3 Dysregulation.胶质母细胞瘤患者 T 细胞和 NK 细胞活性降低与 TIM-3 和 BAT3 失调有关。
Cells. 2024 Oct 26;13(21):1777. doi: 10.3390/cells13211777.
10
Status Quo in the Liposome-Based Therapeutic Strategies Against Glioblastoma: "Targeting the Tumor and Tumor Microenvironment".基于脂质体的胶质母细胞瘤治疗策略的现状：“靶向肿瘤和肿瘤微环境”。
Int J Mol Sci. 2024 Oct 19;25(20):11271. doi: 10.3390/ijms252011271.
本文引用的文献
1
Viral and other therapies for recurrent glioblastoma: is a 24-month durable response unusual?病毒和其他疗法治疗复发性胶质母细胞瘤：24 个月的持久缓解罕见吗？
Neuro Oncol. 2019 Jan 1;21(1):14-25. doi: 10.1093/neuonc/noy170.
2
Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Urothelial Bladder Carcinoma (PURE-01): An Open-Label, Single-Arm, Phase II Study.帕博利珠单抗作为肌层浸润性尿路上皮膀胱癌根治性切除术的新辅助治疗（PURE-01）：一项开放标签、单臂、Ⅱ期研究。
J Clin Oncol. 2018 Dec 1;36(34):3353-3360. doi: 10.1200/JCO.18.01148. Epub 2018 Oct 20.
3
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy.泛肿瘤基因组生物标志物用于基于 PD-1 检查点阻断的免疫治疗。
Science. 2018 Oct 12;362(6411). doi: 10.1126/science.aar3593.
4
Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer.基线类固醇对非小细胞肺癌患者程序性细胞死亡-1 和程序性死亡配体 1 阻断疗效的影响。
J Clin Oncol. 2018 Oct 1;36(28):2872-2878. doi: 10.1200/JCO.2018.79.0006. Epub 2018 Aug 20.
5
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors.在脑胶质瘤和其他颅内肿瘤的情况下，T 细胞在骨髓中的隔离。
Nat Med. 2018 Sep;24(9):1459-1468. doi: 10.1038/s41591-018-0135-2. Epub 2018 Aug 13.
6
Viruses in cancer therapy - from benchwarmers to quarterbacks.癌症治疗中的病毒——从板凳球员到四分卫。
Nat Rev Clin Oncol. 2018 Nov;15(11):657-658. doi: 10.1038/s41571-018-0077-0.
7
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.初现曙光：自体树突状细胞瘤疫苗治疗新诊断胶质母细胞瘤 III 期临床试验的生存结果。
J Transl Med. 2018 May 29;16(1):142. doi: 10.1186/s12967-018-1507-6.
8
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.接受 Toca 511 + Toca FC 治疗的某些复发性高级别脑胶质瘤患者中获得持久完全缓解。
Neuro Oncol. 2018 Sep 3;20(10):1383-1392. doi: 10.1093/neuonc/noy075.
9
Regulated intratumoral expression of IL-12 using a RheoSwitch Therapeutic System (RTS) gene switch as gene therapy for the treatment of glioma.使用 RheoSwitch 治疗系统（RTS）基因开关调控肿瘤内 IL-12 的表达作为基因治疗胶质母细胞瘤。
Cancer Gene Ther. 2018 Jun;25(5-6):106-116. doi: 10.1038/s41417-018-0019-0. Epub 2018 May 14.
10
Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia.慢性淋巴细胞白血病中 CD19 嵌合抗原受体 (CAR) T 细胞治疗应答和耐药的决定因素。
Nat Med. 2018 May;24(5):563-571. doi: 10.1038/s41591-018-0010-1. Epub 2018 Apr 30.
Zotero 插件